Co-Diagnostics
CODXCo-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company based in the United States. Its primary business focus is the development, manufacturing, and marketing of diagnostic tests. The company's operations are centered on its proprietary CoPrimer™ technology platform, which is designed for the detection of nucleic acid molecules. This technology forms the foundation for its suite of diagnostic products, including tests for infectious diseases. The company's key diagnostic areas include tests for tuberculosis, hepatitis B and C, HPV, malaria, and SARS-CoV-2. Co-Diagnostics manufactures its tests at its FDA-registered and ISO 13485-certified facility in Salt Lake City, Utah. The company markets its products globally through a distribution network that serves clinical, research, and public health markets. Its product portfolio encompasses reagents for use on open-channel PCR systems as well as fully integrated test kits. As a publicly traded entity, Co-Diagnostics also engages in the sale of its CoPrimer™ technology and related reagents to other diagnostic companies and research institutions through its subsidiary, CoSara Diagnostics. This includes providing design services and licensing for the development of assays by third parties. The company's financial and operational disclosures are made in accordance with its reporting obligations as a Nasdaq-listed company.
CODX · Stock Price
Historical price data
About
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company based in the United States. Its primary business focus is the development, manufacturing, and marketing of diagnostic tests. The company's operations are centered on its proprietary CoPrimer™ technology platform, which is designed for the detection of nucleic acid molecules. This technology forms the foundation for its suite of diagnostic products, including tests for infectious diseases. The company's key diagnostic areas include tests for tuberculosis, hepatitis B and C, HPV, malaria, and SARS-CoV-2. Co-Diagnostics manufactures its tests at its FDA-registered and ISO 13485-certified facility in Salt Lake City, Utah. The company markets its products globally through a distribution network that serves clinical, research, and public health markets. Its product portfolio encompasses reagents for use on open-channel PCR systems as well as fully integrated test kits. As a publicly traded entity, Co-Diagnostics also engages in the sale of its CoPrimer™ technology and related reagents to other diagnostic companies and research institutions through its subsidiary, CoSara Diagnostics. This includes providing design services and licensing for the development of assays by third parties. The company's financial and operational disclosures are made in accordance with its reporting obligations as a Nasdaq-listed company.